Introduction:

Subcutaneous Biologics Market was valued at US$ 205.2 billion in 2024 and is projected to grow at a CAGR of 12.3% to reach US$ 656.3 billion by 2034.

Biologic is also called as biopharmaceutical; it is a complex therapeutic product produced by a biological process. Biologics such as vaccines, body proteins, somatic cells, plasma, and blood-derived products. Biologics market has a lucrative opportunity due to its broad application. Most of the biologics are given intravenously. In the past years, various biologics has given subcutaneously. This route of administration has important advantages over the intravenous mode of administration such as it doesn’t require any skilled person for drug administration and allow at-home drug delivery, hence it reduces time, medicine cost and increased therapy compliance. Due to its above-mentioned facts, subcutaneous mode of administration is highly-effective while administrating proteins, peptides, vaccines, antibodies, and another complex molecule. In turn, it is expected to fuel the subcutaneous biologics market growth over the forecast period.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Prevalence of diseases such as cancer, tumors etc.

As of now, the prevalence of diseases such as cancer, tumors, and autoimmune diseases followed by increasing research & development activity on biologics is anticipated to boost the subcutaneous biologics market for over the forecast period.

Additionally, increasing focus on the biologic products is a key factor fueling the overall market growth. In addition to this, government initiatives for the awareness of vaccines in emerging countries are likely to propel the growth of the subcutaneous biologics market during the forecast period.

Subcutaneous Biologics market is segmented based on Subcutaneous Drug Delivery System, Application and region.

On the basis of Subcutaneous Drug Delivery System, the Subcutaneous Biologics market is segmented into Prefilled Syringe, Wearable Injectors, Auto-Injectors, and Drug Reconstitution Delivery Systems. On the basis of Application, the target market is segmented into Crohn’s Disease, Rheumatoid Arthritis, Breast Cancer, Leukemia, Lymphoma, and Psoriasis.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Subcutaneous Biologics Market Regional Insights

On region the Subcutaneous Biologics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account major market share as compared to that of other regions owing to increasing presence of biopharmaceutical industries with increasing demand of precision medicine.

Report Scope:

Attribute	Details
Market Size 2024	US$ 205.2 billion
Projected Market Size 2034	US$ 656.3 billion
CAGR Growth Rate	12.3%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Subcutaneous Drug Delivery System- Prefilled Syringe, Wearable Injectors, Auto-Injectors, and Drug Reconstitution Delivery Systems By Application– Crohn’s Disease, Rheumatoid Arthritis, Breast Cancer, Leukemia, Lymphoma, and Psoriasis
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Subcutaneous Biologics Market report based on Subcutaneous Drug Delivery System, Application and region:

Subcutaneous Biologics Market, By Subcutaneous Drug Delivery System:

• Prefilled Syringe
• Wearable Injectors
• Auto-Injectors
• Drug Reconstitution Delivery Systems

Subcutaneous Biologics Market, By Application:

• Crohn’s Disease
• Rheumatoid Arthritis
• Breast Cancer
• Leukemia
• Lymphoma
• Psoriasis

Subcutaneous Biologics Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Key players operating in the market of subcutaneous biologics include AbbVie, Inc., Biogen Idec, F. Hoffmann-La, Takeda Pharmaceutical Company Ltd., Roche AG, Genentech Inc., Amgen, Inc., Eisai, Inc., Pfizer Ltd., and Bristol-Myers Squibb.

• AbbVie, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Biogen Idec
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• F. Hoffmann-La
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Takeda Pharmaceutical Company Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Roche AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Genentech Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Amgen, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Eisai, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Pfizer Ltd
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bristol-Myers Squibb
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

“*” marked represents similar segmentation in other categories in the respective section

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
   • PORTER’s
   • Investment Outlook
3. Market Purview
   • Executive Summary
   • Key Findings—Global Outlook for Subcutaneous Biologics Market Strategies
     • Key Questions this Study will Answer
     • By Subcutaneous Drug Delivery Systems (Prefilled Syringe, Wearable Injectors, Auto-Injectors, and Drug Reconstitution Delivery Systems)
     • By Application (Crohn’s Disease, Rheumatoid Arthritis, Breast Cancer, Leukemia, Lymphoma, and Psoriasis)
     • By Region (North America, Europe, Asia Pacific, Latin America, Middle East, Africa)
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restraints
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Overview
   • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
   • Y-o-Y Growth Analysis (%), 2020 – 2030
   • Regional Trends
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Regional Analysis
   • Regional Revenue Analysis
   • Regional By segment Analysis
   • Reasons for regional growth
   • Key Player of particular region
   • Countries Include in the report:

1. • • North America (U.S., Canada)
     • Europe (UK, France, Germany, Russia, Italy, Rest of Europe)
     • Asia Pacific (India, Japan, South Korea, China, Rest of Asia Pacific)
     • Latin America (Brazil, Mexico, Rest of Latin America)
     • Middle East & Africa (GCC, Israel, South Africa, Rest of Middle East)

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis
   • Competitive Overview
   • Competitive Benchmarking
   • Market Share Analysis
   • Key Developments In The Global Subcutaneous Biologics Market Market
   • Key Developments: Mergers & Acquisitions
   • Key Developments: Collaboration
   • Key Developments: Contracts & Agreements
   • Key Developments: Expansion
   • Key Developments: Product Developments
2. Company Profiles

 

• Company Overview
• Product Portfolio
• Key Highlights
• Financial Performance
• Business Strategies
• SWOT Analysis

• AbbVie, Inc., Biogen Idec, F. Hoffmann-La, Takeda Pharmaceutical Company Ltd., Roche AG, Genentech Inc., Amgen, Inc., Eisai, Inc., Pfizer Ltd., and Bristol-Myers Squibb.

The Last Word

• Future Impact
• About Us
• Contact